Anti-tim-3 antigen antibody or antibody derivative, and use thereof
US-2024391997-A1 · Nov 28, 2024 · US
Immunotoxin for treating cancer
US11713351B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11713351-B2 |
| Application number | US-202017076409-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 21, 2020 |
| Priority date | Apr 30, 2003 |
| Publication date | Aug 1, 2023 |
| Grant date | Aug 1, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A nucleic acid encoding an immunotoxin comprising amino acid 23 to amino acid 669 of SEQ ID NO: 2. 2. The nucleic acid sequence of claim 1 wherein the amino acid sequence consists of amino acid 23 to amino acid 669 of SEQ ID NO: 2. 3. A nucleic acid encoding an immunotoxin comprising the amino acid sequence of SEQ ID NO: 2. 4. The nucleic acid sequence of claim 3 wherein the amino acid sequence consists of the amino sequence of SEQ ID NO: 2. 5. A nucleic acid encoding the immunotoxin comprising the amino acid sequence according to SEQ ID NO: 3. 6. The nucleic acid of claim 5 where the amino acid sequence consists of SEQ ID NO: 3. 7. A kit comprising the nucleic acid sequence of claim 1 . 8. A kit comprising the nucleic acid sequence of claim 2 . 9. A kit comprising the nucleic acid sequence of claim 3 . 10. A kit comprising the nucleic acid sequence of claim 4 . 11. A kit comprising the nucleic acid sequence of claim 5 . 12. A kit comprising the nucleic acid sequence of claim 6 .
Assignees
Inventors
Classifications
- C07K16/28Primary
against receptors, cell surface antigens or cell surface determinants · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A · CPC title
the tumour determinant being from kidney or bladder cancer cell · CPC title
the tumour determinant being from skin, nerves or brain cancer cell · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11713351B2 cover?
- The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or …
- Who is the assignee on this patent?
- Univ Zuerich, Univ Of Zuerich
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).